Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism and Excretion of [14C]Chiauranib in SCLC
NCT05371899Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of chiauranib in small cell lung cancer (SCLC), sponsored by Akeso, Inc. Primary endpoints: Time to Maximum Plasma Concentration up to 22 days, Maximum Plasma Concentration up to 22 days and 6 more. Started Jul 2022; status: completed.
02
Drugs
chiauranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05371899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371899.